15 Most Promising Mid-Cap Healthcare Stocks Under $50

Page 11 of 15

5. Denali Therapeutics (NASDAQ:DNLI)

Sector/Industry: Healthcare (Biotechnology)

Share Price: $16.85

Potential Upside: 83.9%

Number of Hedge Fund Holders: 36

Denali Therapeutics (NASDAQ:DNLI) is one of the most promising mid-cap healthcare stocks under $50.

On December 11, Wedbush analyst Laura Chico maintained her bullish stance on Denali Therapeutics (NASDAQ:DNLI). She rated the stock Buy with a $30 target price, implying a notable 78% upside for investors.

Chico’s price target is a revision from the previous target of $31, but this comes after the company’s completion of a recent $200 million secondary offering. The company issued 9.1 million additional common shares at $17.50 per share. The issuance also involved pre-funded warrants to buy an additional 2.3 million common shares. Chico estimated the overall net proceeds from this offering to be in the range of $217 million. She sees such equity financing to be logical at a time when the company is engaged with the FDA regarding a potential tivi PRV issuance.

Besides that, Denali Therapeutics (NASDAQ:DNLI) stock has received Buy calls from all 11 analysts by the close of play on December 19. According to analyst estimates, the stock’s median 1-year price target is $31 per share, implying nearly 84% upside at current market levels.

Denali Therapeutics (NASDAQ:DNLI) is a biotechnology company that utilizes proprietary technology to address neurodegenerative diseases. Through their TransportVehicle™ platform, and by leveraging the power of biotherapeutics, they develop medicines for some very serious conditions, including lysosomal storage.

Page 11 of 15